Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CYTOF · OTC · United States · Pharmaceutical Preparations
In shortAltamira Therapeutics Ltd. is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1560976.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -1020890.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | n/a |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.38× | 48/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -5.87× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -7.04 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -3037220.1% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 2 | 17/100 |
| Revenue growth volatility | 338.2% | 0/100 |
| Operating margin volatility | 896426.6% | 0/100 |
Weight in the score: 20%
Fiscal year 2023 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
CHF millions; negative values in parentheses.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 |
|---|---|---|---|---|---|
| Revenue | – | – | 0.1 | 0.3 | 0 |
| Cost of revenue | – | – | 2.2 | 1.4 | 0 |
| Gross profit | – | – | (2.2) | (1.1) | (0) |
| Research & development | 3.3 | 2.9 | 3.2 | 15 | 3 |
| Selling, general & admin | – | 2.6 | 3.7 | 3.4 | 3.1 |
| Operating income | (7.3) | (5.3) | (6.9) | (18) | (5.9) |
| Interest expense | 1.6 | 6.1 | 1.7 | 1.6 | 1 |
| Pre-tax income | (6.8) | (8.2) | (6.8) | (19) | (7.3) |
| Income tax | (0.2) | (0) | (0.1) | (0) | – |
| Net income | (6.6) | (8.2) | (17) | (27) | (3.9) |
| Diluted EPS | −CHF2.28 | −CHF25.27 | −CHF515.11 | −CHF582.58 | −CHF7.88 |
| Diluted shares (millions) | 0.8 | 0.6 | 0.7 | 0.9 | 0 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
−7.04 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2024 · Data updated Apr 30, 2025